Halozyme

Roche hits FDA delay with subcutaneous version of Tecentriq amid manufacturing process changes
Roche hits FDA delay with subcutaneous version of Tecentriq amid manufacturing process changes
Fierce Pharma
Roche
FDA
Tecentriq
Halozyme
Flag link:
Focus: Drugmakers go under the skin, skirting early US Medicare price negotiations
Focus: Drugmakers go under the skin, skirting early US Medicare price negotiations
Reuters
injectables
cancer
JNJ
Bristol Myers Squibb
Halozyme
drug pricing
Flag link:
Biopharma's stock market winners of 2022 revealed
Biopharma's stock market winners of 2022 revealed
EP Vantage
pharma stocks
Merck
Eli Lilly
AbbVie
Daiichi Sankyo
Vertex Pharmaceuticals
Takeda
Sarepta Therapeutics
Halozyme
Horizon Therapeutics
Flag link:
If at first... pharma’s most drawn-out development timelines revealed
If at first... pharma’s most drawn-out development timelines revealed
EP Vantage
Kyowa Kirin
Takeda
Eiger BioPharmaceuticals
AstraZeneca
Teva Pharmaceutical
Bavarian Nordic
Halozyme
Novartis
MannKind
drug development
Flag link:
The Big Winner With Johnson & Johnson's Recent FDA Approval
The Big Winner With Johnson & Johnson's Recent FDA Approval
Motley Fool
JNJ
FDA
Darzalex Faspro
Halozyme
Flag link:
Pair of R&D updates bolster GSK ahead of investor meeting
Pair of R&D updates bolster GSK ahead of investor meeting
Pharmaforum
GSK
COVID-19
sotrovimab
Halozyme
investors
Flag link:
J&J’s next-gen Darzalex sparks drug delivery royalties battle
J&J’s next-gen Darzalex sparks drug delivery royalties battle
Fierce Pharma
JNJ
Darzalex
Genmab
Halozyme
Flag link:
After Ending Cancer Drug Program, Halozyme Predicts Profits in 2020
After Ending Cancer Drug Program, Halozyme Predicts Profits in 2020
Xconomy
Halozyme
clinical trials
drug delivery
Enhanze
Flag link:
Halozyme drops PFS co-primary endpoint from PEGPH20 phase 3
Halozyme drops PFS co-primary endpoint from PEGPH20 phase 3
Fierce Biotech
Halozyme
clinical trials
PEGPH20
metastatic prostate cancer
Flag link:
Halozyme, Inovalon, and Teva Soared This Week: Can They Go Higher?
Halozyme, Inovalon, and Teva Soared This Week: Can They Go Higher?
Motley Fool
Halozyme
Inovalon
Teva Pharmaceutical
Unitedhealthcare Group
Roche
Bristol-Myers Squibb
Flag link:
Bristol To Pay Halozyme $105 Million To Make New Cancer Drugs Easier To Take
Bristol To Pay Halozyme $105 Million To Make New Cancer Drugs Easier To Take
Forbes
Bristol-Myers Squibb
Halozyme
Opdivo
Flag link:
Halozyme Cancer Drug Does Well in Phase 2
Halozyme Cancer Drug Does Well in Phase 2
Investopedia
Halozyme
pancreatic cancer
clinical trials
PEGPH20
Eli Lilly
Celgene
gemcitabine
Abraxane
Flag link:
AbbVie Ends Halozyme Development Deal
AbbVie Ends Halozyme Development Deal
Investopedia
AbbVie
Halozyme
tnf-alpha
drug development
drug delivery
Flag link:
Halozyme shares drop after AbbVie punts a failed program; Celgene buys another cancer drug
Halozyme shares drop after AbbVie punts a failed program; Celgene buys another cancer drug
Endpoints
Halozyme
AbbVie
Celgene
marizomib
Flag link:
Halozyme Therapeutics reports 3Q loss
Halozyme Therapeutics reports 3Q loss
Yahoo/AP
earnings
Halozyme
Flag link:
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
Yahoo
FDA
Genentech
Halozyme
rituximab
blood cancer
Flag link:
3 Top Biopharma Movers of the Past Week
3 Top Biopharma Movers of the Past Week
24/7 Wall St
Vitae
Juno Therapeutics
Halozyme
Flag link:
Halozyme Therapeutics beats 4Q profit forecasts
Halozyme Therapeutics beats 4Q profit forecasts
Yahoo/AP
Halozyme
earnings
Flag link:
4 Top BioPharma Movers of the Past Week
4 Top BioPharma Movers of the Past Week
24/7 Wall St
Anavex
Affymetrix
Thermofisher
Halozyme
Flag link:
Eli Lilly taps Halozyme in an $825M delivery deal
Eli Lilly taps Halozyme in an $825M delivery deal
Fierce Biotech
Eli Lilly
Halozyme
drug delivery
Enhanze
Flag link:

Pages